Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study (Q84310525)
Jump to navigation
Jump to search
scientific article published on 01 August 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study |
scientific article published on 01 August 2010 |
Statements
Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study (English)
Stanislaw Sierakowski
Mikkel Østergaard
Bo Baslund
William Rigby
Bernadette Rojkovich
Christian Jorgensen
Peter T Dawes
Charlotte Wiell
Daniel J Wallace
Søren C Tamer
Helle Kastberg
Jørgen Petersen